Biological immunotherapy for advanced bone cancer

Biological immunotherapy for the treatment of advanced bone cancer is an applied study of personalized cell therapy for bone cancer based on dendritic cells (DC). The combined use of DC vaccines and cytokine-induced killer cells (CIK) can significantly improve the patient's survival and quality of life.

Studies have found that DC vaccines play an important role in the body's defense against malignant tumors and infectious diseases. CIK cells have both the powerful anti-tumor activity of T lymphocytes and the broad-spectrum tumor-killing advantages of natural killer cells (NK). The combined use of the two has a synergistic effect. The DC cells produced after co-incubation can improve the expression of stimulating molecules and antigen presentation capabilities, and the killing activity of CIK is further enhanced, which has broad prospects for clinical application.

Biological immunotherapy for the treatment of advanced bone cancer has the following advantages: a wide range of applications, and can be applied to almost all cancer patients; it has obvious therapeutic effects on primary tumors and metastatic tumors; it has a more obvious effect than chemotherapy in clearing residual cancer cells in patients with malignant tumors after surgery and preventing tumor recurrence; it also has a good effect on patients who cannot undergo radiotherapy or chemotherapy; it has small side effects, does not damage normal tissues, and can enhance the body's immunity and improve physical condition after radiotherapy and chemotherapy.